BridgeBio Pharma BBIO Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's shares (diluted)?
- BridgeBio Pharma (BBIO) reported shares (diluted) of 194.8M in Q1 2026.
- How has BridgeBio Pharma's shares (diluted) changed year-over-year?
- BridgeBio Pharma's shares (diluted) increased by 2.4% year-over-year, from 190.1M to 194.8M.
- What is the long-term trend for BridgeBio Pharma's shares (diluted)?
- Over 4 years (2021 to 2025), BridgeBio Pharma's shares (diluted) has grown at a 7.3% compound annual growth rate (CAGR), from 576.4M to 764M.
- What does shares (diluted) mean?
- The total number of shares that would exist if all potential sources of share dilution were converted into common stock.
- How do you interpret shares (diluted)?
- An increase in this metric indicates potential dilution for existing shareholders, often resulting from the issuance of stock-based compensation or the conversion of debt instruments. A decrease typically suggests share buybacks or a reduction in outstanding dilutive securities.
- How does shares (diluted) compare across companies?
- Standardized across all public companies, this metric is directly comparable to peers and is a fundamental component of standardized EPS reporting under GAAP/IFRS.